Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ViroMissile, Inc.
Arcus Biosciences, Inc.
Tizona Therapeutics, Inc
Canadian Cancer Trials Group
Poseida Therapeutics, Inc.
MacroGenics
City of Hope Medical Center
Novartis
GlaxoSmithKline
NeoTX Therapeutics Ltd.
Bolt Biotherapeutics, Inc.
Nanobiotix
Actym Therapeutics, Inc.
Janux Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
Exelixis
Xencor, Inc.
NextPoint Therapeutics, Inc.
Sotio Biotech Inc.
Novartis
Eli Lilly and Company
AstraZeneca
NGM Biopharmaceuticals, Inc
Xencor, Inc.
Pfizer
ADC Therapeutics S.A.
Pliant Therapeutics, Inc.
DNAtrix, Inc.
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
HiberCell, Inc.
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Fate Therapeutics
Canadian Cancer Trials Group
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Evelo Biosciences, Inc.
Novartis
Xencor, Inc.
Ludwig Institute for Cancer Research
Calithera Biosciences, Inc
Incyte Corporation
MacroGenics
MacroGenics
MacroGenics
Incyte Corporation